Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection | Zendy

Mark Sulkowski | Zendy; David Gardiner | Zendy; M. RodríguezTorres | Zendy; K. Rajender Reddy | Zendy; Tarek Hassanein | Zendy; Ira M. Jacobson | Zendy; Eric Lawitz | Zendy; Anna S. Lok | Zendy; Federico Hinestrosa | Zendy; Paul J. Thuluvath | Zendy; Howard Schwartz | Zendy; David R. Nelson | Zendy; Gregory T. Everson | Zendy; Timothy Eley | Zendy; Megan WindRotolo | Zendy; Shu-Pang Huang | Zendy; Min Gao | Zendy; Dennis Hernandez | Zendy; Fiona McPhee | Zendy; Diane L. Sherman | Zendy; R. Hindes | Zendy; William T. Symonds | Zendy; C Pasquinelli | Zendy; Dennis M. Grasela | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection

Author(s) -

Mark Sulkowski,

David Gardiner,

M. RodríguezTorres,

K. Rajender Reddy,

Tarek Hassanein,

Ira M. Jacobson,

Eric Lawitz,

Anna S. Lok,

Federico Hinestrosa,

Paul J. Thuluvath,

Howard Schwartz,

David R. Nelson,

Gregory T. Everson,

Timothy Eley,

Megan WindRotolo,

Shu-Pang Huang,

Min Gao,

Dennis Hernandez,

Fiona McPhee,

Diane L. Sherman,

R. Hindes,

William T. Symonds,

C Pasquinelli,

Dennis M. Grasela

Publication year - 2014

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1306218

Subject(s) - daclatasvir , sofosbuvir , ns5a , medicine , ns5b , virology , hepatitis c virus , genotype , chronic hepatitis , hepacivirus , virus , ribavirin , gene , biology , genetics

All-oral combination therapy is desirable for patients with chronic hepatitis C virus (HCV) infection. We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) plus sofosbuvir (a nucleotide analogue HCV NS5B polymerase inhibitor) in patients infected with HCV genotype 1, 2, or 3.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research